Clinical trial · Observational
PET/CT Based Radiomics for Lung Cancer (PERL)
PET/CTbased Radiomics for Lung Cancer (PERL): a Retrospective Multi-center Study
NCT03517306CI-TRIAL-00037947unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators investigate the utility of FDG PET/CT based radiomics in lung cancer, including diagnosis and prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Interventions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Beijing
- description
- No interventions
- interventionNames
- Other: No Interventions
- label
- Ningxia
- description
- No interventions
- interventionNames
- Other: No Interventions
- label
- Wenzhou
- description
- No interventions
- interventionNames
- Other: No Interventions
- label
- Changzhou
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- All patients diagnosed as lung cancer patients who had a FDG PET/CT scan before treatment between 1 Jan, 2013 and 30 December, 2016 in the four collaborative hospitals. Exclusion Criteria: \- The patient without follow-up information
References
Publications (0)
Data not yet available
No reference posted for this study.